Search

Your search keyword '"Kaufman, Ronald P."' showing total 213 results

Search Constraints

Start Over You searched for: Author "Kaufman, Ronald P." Remove constraint Author: "Kaufman, Ronald P."
213 results on '"Kaufman, Ronald P."'

Search Results

2. Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results.

4. Reply by Authors

6. ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC).

10. Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study

13. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia

20. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3‐year trial results

21. PD18-06 AQUABLATION FOR BENIGN PROSTATIC HYPERPLASIA IN LARGE PROSTATES (80-150CC): 3-YEAR RESULTS

25. Survivin and Bcl-2 expression in prostatic Adenocarcinomas

28. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results

29. Reply by Authors

30. Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease

36. PD20-02 EFFICACY AND SAFETY OF PADELIPORFIN VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG UTUC): PHASE 3 PRELIMINARY RESULTS.

37. MP20-01 WATER vs WATER II 3-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80 cc and 80-150 cc Prostates.

38. Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained

39. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial

47. Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial

48. WATER II (80-150 mL) procedural outcomes

49. Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs.

50. Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs.

Catalog

Books, media, physical & digital resources